Amr Mansouri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amr Mansouri has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hazim Allos
Section of Infectious Disease, Department of Medicine, UTHealth Science Center, McGovern Medical School, Houston, USA
2 shared publications - Ina Sulkaj
Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Jamil R. Azzi
Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
2 shared publications - John Y. Choi
Transplant Research Center, Division of Renal Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America
2 shared publications - Juliano Alhaddad
Department of Medicine, Boston Medical Center Brighton, Boston, USA
2 shared publications - Siawosh K. Eskandari
Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 shared publications
Latest Publications
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.
- 11 November 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (569)
Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter
Adoptive cell transfer of ex vivo expanded regulatory T cells (Tregs) has shown immense potential in animal models of auto- and alloimmunity. However, the effective translation of such Treg therapies to the clinic has been slow. Because Treg homeostasis is known to require continuous T cell receptor (TCR) ligation and exogenous interleukin-2 (IL-2), some investigators have explored the use of low-dose IL-2 injections to increase endogenous Treg responses. Systemic IL-2 immunotherapy, however, can also lead to the activation of cytotoxic T lymphocytes and natural killer cells, causing adverse therapeutic outcomes. Here, we describe a drug delivery platform, which can be engineered to autostimulate Tregs with IL-2 in response to TCR-dependent activation, and thus activate these cells in sites of antigen encounter. To this end, protein nanogels (NGs) were synthesized with cleavable bis(N-hydroxysuccinimide) cross-linkers and IL-2/Fc fusion (IL-2) proteins to form particles that release IL-2 under reducing conditions, as found at the surface of T cells receiving stimulation through the TCR. Tregs surface-conjugated with IL-2 NGs were found to have preferential, allograft-protective effects relative to unmodified Tregs or Tregs stimulated with systemic IL-2. We demonstrate that murine and human NG–modified Tregs carrying an IL-2 cargo perform better than conventional Tregs in suppressing alloimmunity in murine and humanized mouse allotransplantation models. In all, the technology presented in this study has the potential to improve Treg transfer therapy by enabling the regulated spatiotemporal provision of IL-2 to antigen-primed Tregs.
- Open Access
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Regulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.
- 28 February 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (11) , 6042-6046
Open AccessRegulatory CD8 T cells that recognize Qa-1 expressed by CD4 T-helper cells inhibit rejection of heart allografts
Significance: There is increasing evidence that CD8 + regulatory T cells (CD8 Treg) can modulate the immune response in the context of autoimmune disease, infection, and cancer. Here we asked whether this regulatory mechanism might control the host response to transplanted heart allografts. We report that CD8 Treg that recognize Qa-1, the murine homolog of HLA-E, strongly inhibits host production of antibodies specific for the donor organ. Since the production of antidonor antibodies is currently a major barrier to successful transplantation, identification of this Qa-1/HLA-E-dependent pathway may pave the way to approaches to this pressing clinical problem.